# The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc

Source: https://onco.cc/trials/nct05496166/  
OnCo record `nct05496166` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Shanghai Pulmonary Hospital, Shanghai, China, not yet recruiting.

## Summary

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05496166 by Shanghai Pulmonary Hospital, Shanghai, China, with a registry enrolment figure of 348 participants, started 2023-08-01 and due to reach its primary completion in 2027-08-01. Interventions recorded: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy. Conditions listed: Limited Stage Small Cell Lung Cancer. Primary outcome: progression-free survival. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed SCLC, imaging examination and other confirmed limited-stage small cell lung cancer, and without previous treatment;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05496166
- Phase: 3
- Setting: Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical Trial
- Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
- Enrolled: 348

## Sources

- ClinicalTrials.gov NCT05496166: https://clinicaltrials.gov/study/NCT05496166

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05496166.json